Vividion Therapeutics is developing selective small molecules for cancer and immune disorders. Despite technical advances, about 90% of disease-causing proteins cannot be targeted with therapeutics because effective binding sites have not been found. To find previously unknown and functional protein binding pockets and small molecules that bind them, Vividion is using their chemoproteomic platform technology. The platform addresses key limitations of conventional screening techniques through the use of expertise in chemistry, biology and drug development. Vividion is advancing a diversified pipeline with lead programs targeting NRF2, STAT3 and WRN, all disease-causing proteins in oncology and immunology.

<p>Vividion Therapeutics is developing selective small molecules for cancer and immune disorders. Despite technical advances, about 90% of disease-causing proteins cannot be targeted with therapeutics because effective binding sites have not been found. To find previously unknown and functional protein binding pockets and small molecules that bind them, Vividion is using their chemoproteomic platform technology. The platform addresses key limitations of conventional screening techniques through the use of expertise in chemistry, biology and drug development. Vividion is advancing a diversified pipeline with lead programs targeting NRF2, STAT3 and WRN, all disease-causing proteins in oncology and immunology.</p>


Vividion Therapeutics

Founded: 2014
Location: San Diego, CA
Employee range: 50 - 200
Clinical stage: Clin0
Therapy area: Oncology
Drug types: ONC, IMM, GI
Lead product: Undisclosed
Funding: $135M C Feb 2021; $82M Apr 2019; $45M A Feb 2017

Drug notes:

About:

Jobs: